Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) to a hold rating in a research note issued to investors on Saturday morning.

Lakewood-Amedex Biotherapeutics Trading Up 28.9%

NASDAQ LABT opened at $3.43 on Friday. Lakewood-Amedex Biotherapeutics has a 52 week low of $2.58 and a 52 week high of $9.82.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.